Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 0.9 Normal Saline Clear all

Conditions: Ehlers-Danlos Syndrome, Anesthesia, Local
Interventions: 0.9% Sodium Chloride Injection, Lidocaine Injection 2%, Bupivacaine Injection 0.5%; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Telangiectasia, Hereditary Hemorrhagic, Epistaxis
Interventions: Sterile saline, Bevacizumab, Estriol, Tranexamic Acid; Drug
Lead sponsor: James Gossage; Other
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 6
States / cities: Los Angeles, California • Augusta, Georgia • Baltimore, Maryland + 3 more

Conditions: HIV Infections, Dyslipidemias
Interventions: Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein), Saline Solution; Drug
Lead sponsor: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 50 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hemorrhage, Surgical, Tonsillar Bleeding
Interventions: Tranexamic Acid Injectable Product, Normal Saline; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 2 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Davis, California • Providence, Rhode Island • San Antonio, Texas

Conditions: Mohs Surgery
Interventions: EB-001, 0.9% Sodium Chloride Injection; Drug
Lead sponsor: Bonti, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Systemic Allergic Reaction
Interventions: Pfizer-BioNTech COVID-19 Vaccine (Comirnaty), Placebo, Pfizer-BioNTech COVID-19 Vaccine, Bivalent; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years to 69 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer, Tumour, Surgery
Interventions: Tranexamic acid (TXA), Normal saline; Drug
Lead sponsor: Sunnybrook Health Sciences Centre; Other
Eligibility: 18 Years and older
Enrollment: 1,386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: COVID, COVID-19, Corona Virus Infection
Interventions: Sarilumab 200 MG/1.14 ML Subcutaneous Solution, Placebo; Drug
Lead sponsor: BayCare Health System; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 3
States / cities: Clearwater, Florida • St. Petersburg, Florida • Tampa, Florida

Conditions: Limited Stage Small Cell Lung Cancer
Interventions: Trilaciclib, Saline (0.9% NaCl); Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Oakland, California

Conditions: Homozygous Familial Hypercholesterolemia
Interventions: zodasiran Injection, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Park Ridge, Illinois • New York, New York • Cincinnati, Ohio + 1 more

Conditions: Bowel Obstruction
Interventions: IV morphine sulfate, EXPAREL (bupivacaine liposome injectable suspension); Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Brow Ptosis, Facial Scarring
Interventions: 5-Fluorouracil, Normal Saline Flush, 0.9% Injectable Solution; Drug
Lead sponsor: Eyelid and Facial Consultants; Other
Eligibility: 40 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Houma, Louisiana • New Orleans, Louisiana

Conditions: Fractures, Open
Interventions: Tobramycin, Placebo: normal saline; Drug · Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 70 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Covid19
Interventions: Remdesivir, Remdesivir Placebo, Aviptadil, Aviptadil Placebo, Corticosteroid; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 40
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more

Conditions: Postoperative Pain
Interventions: Methadone, Saline; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Osteoarthritis, Osteoarthritis, Knee, Arthritis, Degenerative, Osteoarthrosis, Osteoarthrosis Deformans
Interventions: Bupivacaine Liposome Injection, Indwelling femoral nerve block; Drug
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: Diabetic Kidney Disease, Hyperuricemia, Diabetes, Diabetes Mellitus, Type 2, Type2 Diabetes, Type 2 Diabetes Mellitus, Diabetic Nephropathies, Diabetes Complications
Interventions: Pegloticase 8 MG/ML [Krystexxa]; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 25 Years · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Osteoarthritis, Knee
Interventions: Cingal, Triamcinolone Hexacetonide (TH), Placebo; Drug
Lead sponsor: Anika Therapeutics, Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 26
States / cities: Chandler, Arizona • Tucson, Arizona • Anaheim, California + 21 more

Conditions: Pain, Postoperative, Mammaplasty
Interventions: Dexamethasone 4mg, Saline; Drug
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lumbar Disc Herniation
Interventions: Dexamethasone, saline 0.9%; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Colon Polyps, Colorectal Cancer, Inflammatory Bowel Disease (IBD)
Interventions: Colon KCC Heptapeptide; Biological
Lead sponsor: Danielle Kim Turgeon; Other
Eligibility: 18 Years to 100 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Upper Limb Spasticity
Interventions: DAXI for injection 250 U, DAXI for injection 375 U, DAXI for injection 500 U, Placebo; Biological · Other
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 26
States / cities: Downey, California • Fountain Valley, California • Long Beach, California + 22 more

Conditions: Hemodialysis Complication, Hemodynamic Instability
Interventions: Mannitol, 0.9% saline; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes (T1D)
Interventions: Golimumab, Placebo (matching golimumab); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Years to 44 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers

North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)

TEAPOT Study Multisite

Study of EB-001 in Facial Scar Reduction

The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose

The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial

Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19

Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B302

The Role of 5-Fluorouracil in Post-Operative Scar Formation Following Direct Brow Ptosis Repair

Locally Applied Antibiotics for Infection Prophylaxis in Treatment of Open Fractures

ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19

Methadone Versus Placebo in Spine Fusion

Intraoperative Liposomal Bupivacaine Injection in Primary Total Knee Arthroplasty

Uric Acid Lowering Trial in Youth Onset T2D

Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain

Combination Dexamethasone and Bupivacaine Pain Control in Reduction Mammaplasty

Subjective Intraoperative Use of Epidural Steroid Administration Following Discectomy

Study of KCC Peptide Application in the Colon

Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity

MAnnitol for Blood Pressure Stability in HemoDialysis (MAP-HD)

Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo